ENSCW (Ensysce Biosciences) Margin of Safety % (DCF FCF Based): N/A (As of Jun. 26, 2026)


ENSCW Ensysce Biosciences Inc ENSCW
23 GF Score
Price $0.00
! 2 Warning Signs
View Full Analysis

What is Ensysce Biosciences Margin of Safety % (DCF FCF Based)?

Margin of Safety % (DCF FCF Based) = (Intrinsic Value: DCF (FCF Based) - Current Price) / Intrinsic Value: DCF (FCF Based).

Note: Discounted FCF model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Ensysce Biosciences's Predictability Rank is Not Rated. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF FCF Based) is not calculated.

ENSCW vs PPCB, ACUT, LSBCF: Margin of Safety % (DCF FCF Based) Comparison

For the Biotechnology subindustry, Ensysce Biosciences's Margin of Safety % (DCF FCF Based), along with its competitors' market caps and Margin of Safety % (DCF FCF Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Ensysce Biosciences Margin of Safety % (DCF FCF Based) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ensysce Biosciences's Margin of Safety % (DCF FCF Based) distribution charts can be found below:

* The bar in red indicates where Ensysce Biosciences's Margin of Safety % (DCF FCF Based) falls into.


ENSCW
23GF Score
Ensysce Biosciences Inc ENSCW
Margin of Safety % (DCF FCF Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Ensysce Biosciences Business Description

Other Exchanges ENSC:USA
Address 7946 Ivanhoe Avenue, Suite 201, La Jolla, CA, USA, 92037
Ensysce Biosciences Inc is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is developing a new class of powerful, opioids that prevent both drug abuse and overdoses. Its products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing human and economic costs. The company's current development pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, theTrypsin Activated Abuse Protection, or the TAAP platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant, or the MPAR platform. The Company currently operates in one business segment, which is pharmaceuticals.
23GF Score

Get the complete analysis for ENSCW

Margin of Safety % (DCF FCF Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price